WO2000028090A3 - Diagnostic assay for cancer - Google Patents

Diagnostic assay for cancer Download PDF

Info

Publication number
WO2000028090A3
WO2000028090A3 PCT/US1999/027005 US9927005W WO0028090A3 WO 2000028090 A3 WO2000028090 A3 WO 2000028090A3 US 9927005 W US9927005 W US 9927005W WO 0028090 A3 WO0028090 A3 WO 0028090A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
diagnostic assay
glioblastoma
compositions
methods
Prior art date
Application number
PCT/US1999/027005
Other languages
French (fr)
Other versions
WO2000028090A2 (en
Inventor
Roger A Kroes
Joseph R Moskal
Aaron Jastrow
Hirotaka Yamamoto
Original Assignee
Nyxis Inc
Roger A Kroes
Joseph R Moskal
Aaron Jastrow
Hirotaka Yamamoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nyxis Inc, Roger A Kroes, Joseph R Moskal, Aaron Jastrow, Hirotaka Yamamoto filed Critical Nyxis Inc
Priority to AU17240/00A priority Critical patent/AU1724000A/en
Publication of WO2000028090A2 publication Critical patent/WO2000028090A2/en
Publication of WO2000028090A3 publication Critical patent/WO2000028090A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809Methods for determination or identification of nucleic acids involving differential detection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds

Abstract

The invention is directed towards gene expression characteristic for cancer, in particular brain cancers such as glioblastoma. Compositions, methods and kits encompassing such therein.
PCT/US1999/027005 1998-11-12 1999-11-12 Diagnostic assay for cancer WO2000028090A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU17240/00A AU1724000A (en) 1998-11-12 1999-11-12 Diagnostic assay for cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10812098P 1998-11-12 1998-11-12
US60/108,120 1998-11-12
US14564099P 1999-07-27 1999-07-27
US60/145,640 1999-07-27

Publications (2)

Publication Number Publication Date
WO2000028090A2 WO2000028090A2 (en) 2000-05-18
WO2000028090A3 true WO2000028090A3 (en) 2000-11-16

Family

ID=26805545

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/027005 WO2000028090A2 (en) 1998-11-12 1999-11-12 Diagnostic assay for cancer

Country Status (3)

Country Link
US (3) US6194158B1 (en)
AU (1) AU1724000A (en)
WO (1) WO2000028090A2 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030165888A1 (en) * 2001-07-18 2003-09-04 Brown Bob D. Oligonucleotide probes and primers comprising universal bases for diagnostic purposes
US6518017B1 (en) * 1997-10-02 2003-02-11 Oasis Biosciences Incorporated Combinatorial antisense library
AU777499B2 (en) * 1999-04-08 2004-10-21 Gen-Probe Incorporated Antisense oligonucleotides comprising universal and/or degenerate bases
WO2001036685A2 (en) * 1999-11-17 2001-05-25 Nyxis Neurotherapies, Inc. Differential gene expression in cancer
US6589783B2 (en) * 2000-04-13 2003-07-08 Novagen, Inc. Multiple host expression vector
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US20060259251A1 (en) * 2000-09-08 2006-11-16 Affymetrix, Inc. Computer software products for associating gene expression with genetic variations
IL155450A0 (en) * 2000-10-20 2003-11-23 Expression Diagnostics Inc Leukocyte expression profiling
WO2002040716A2 (en) * 2000-11-16 2002-05-23 Cemines, Llc Profiling tumor specific markers for the diagnosis and treatment of neoplastic disease
US7026121B1 (en) * 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
WO2003002977A1 (en) * 2001-06-29 2003-01-09 Protea Biosciences, Inc. Specimen-linked g protein coupled receptor database
AU2002318437A1 (en) * 2001-06-29 2003-03-03 Clinomics Biosciences, Inc. Evaluating neuropsychiatric diseases using a specimen-linked database
US20070042360A1 (en) * 2001-09-17 2007-02-22 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
CA2459219A1 (en) * 2001-09-17 2003-03-27 Protein Design Labs, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
US7291456B2 (en) 2002-01-24 2007-11-06 The Regents Of The University Of California Method for determining differences in molecular interactions and for screening a combinatorial library
WO2003105773A2 (en) * 2002-06-01 2003-12-24 Oregon Health & Science University Activating mutations of platelet derived growth factor receptor alpha (pdgfra) as diagnostic markers and therapeutic targets:
JP2006512924A (en) * 2002-08-15 2006-04-20 ジェンザイム・コーポレーション Brain endothelial cell expression pattern
US7892745B2 (en) * 2003-04-24 2011-02-22 Xdx, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
JP2006525027A (en) 2003-05-01 2006-11-09 ジェン−プロウブ インコーポレイテッド Oligonucleotides containing molecular switches
WO2006029184A2 (en) * 2004-09-08 2006-03-16 Expression Diagnostics, Inc. Genes useful for diagnosing and monitoring inflammation related disorders
WO2006122295A2 (en) * 2005-05-11 2006-11-16 Expression Diagnostics, Inc. Methods of monitoring functional status of transplants using gene panels
WO2007047907A2 (en) * 2005-10-14 2007-04-26 The Regents Of The University Of Michigan Dek protein compositions and methods of using the same
AU2007309726A1 (en) * 2006-04-07 2008-05-02 Xdx, Inc. Steroid responsive nucleic acid expression and prediction of disease activity
US7993832B2 (en) * 2006-08-14 2011-08-09 Xdx, Inc. Methods and compositions for diagnosing and monitoring the status of transplant rejection and immune disorders
WO2008140484A2 (en) * 2006-11-09 2008-11-20 Xdx, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
WO2009039390A2 (en) * 2007-09-20 2009-03-26 Naurex Inc. The development of glycobiology-based therapeutics for the treatment of brain tumors
AU2009293164B2 (en) 2008-09-18 2015-07-09 Northwestern University NMDA receptor modulators and uses thereof
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
KR101692275B1 (en) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 Secondary structure stabilized nmda receptor modulators and uses thereof
AU2011215704B2 (en) 2010-02-11 2015-07-23 Northwestern University Secondary structure stabilized NMDA receptor modulators and uses thereof
BR112015018095A2 (en) 2013-01-29 2017-07-18 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
ES2935352T3 (en) 2013-01-29 2023-03-06 Aptinyx Inc Spiro-lactam NMDA receptor modulators and their uses
SG11201505934XA (en) 2013-01-29 2015-09-29 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
WO2014120784A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
ES2618421T3 (en) 2013-01-29 2017-06-21 Aptinyx Inc. NMDA receptor spiro-lactam modulators and uses thereof
KR101592305B1 (en) * 2013-10-08 2016-02-05 사회복지법인 삼성생명공익재단 Limiting Dilution Assay for Screening of Patient-specific Anti-cancer Agents
US9459201B2 (en) 2014-09-29 2016-10-04 Zyomed Corp. Systems and methods for noninvasive blood glucose and other analyte detection and measurement using collision computing
US10724091B1 (en) 2015-02-10 2020-07-28 National Technology & Engineering Solutions Of Sandia, Llc Endpoint detection of amplified nucleic acids
US9554738B1 (en) 2016-03-30 2017-01-31 Zyomed Corp. Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20190174A1 (en) 2016-05-19 2019-02-01 Aptinyx Inc SPIRO-LACTAM N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND USES OF THEM
AU2017306152A1 (en) 2016-08-01 2019-01-31 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
PE20190501A1 (en) 2016-08-01 2019-04-10 Aptinyx Inc NMDA ESPIRO-LACTAM MODULATORS AND METHODS OF USE OF THE SAME
EA201990425A1 (en) 2016-08-01 2019-08-30 Аптиникс Инк. SPIRO-LACTAM AND BIS-SPIRO-LACTAM MODULATORS OF THE NMDA RECEPTOR AND THEIR APPLICATION
US10961189B2 (en) 2016-08-01 2021-03-30 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
WO2018026782A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
US11578072B2 (en) 2018-01-31 2023-02-14 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997013877A1 (en) * 1995-10-12 1997-04-17 Lynx Therapeutics, Inc. Measurement of gene expression profiles in toxicity determination
WO1997027317A1 (en) * 1996-01-23 1997-07-31 Affymetrix, Inc. Nucleic acid analysis techniques
WO1998035041A1 (en) * 1997-02-06 1998-08-13 Incyte Pharmaceuticals, Inc. Human lea-motif developmental protein

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5527681A (en) 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5599696A (en) 1989-10-17 1997-02-04 California Institute Of Technology Method of preparing nucleic acids having an undefined nucleotide sequence amplification
US5104792A (en) 1989-12-21 1992-04-14 The United States Of America As Represented By The Department Of Health And Human Services Method for amplifying unknown nucleic acid sequences
US5470970A (en) 1991-02-28 1995-11-28 Dana-Farber Cancer Institute, Inc. Maspin, a serpin with tumor suppresing activity
ATE231920T1 (en) 1992-03-11 2003-02-15 Dana Farber Cancer Inst Inc METHOD TO CLONE MRNA
US5262311A (en) 1992-03-11 1993-11-16 Dana-Farber Cancer Institute, Inc. Methods to clone polyA mRNA
US5744300A (en) 1993-03-24 1998-04-28 Geron Corporation Methods and reagents for the identification and regulation of senescence-related genes
US5580726A (en) 1994-04-29 1996-12-03 Geron Corporation Method and Kit for enhanced differential display
US5744306A (en) 1993-04-19 1998-04-28 Emory University Methods for nucleic acid detection, sequencing, and cloning using exonuclease
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
US5459037A (en) 1993-11-12 1995-10-17 The Scripps Research Institute Method for simultaneous identification of differentially expressed mRNAs and measurement of relative concentrations
US5654419A (en) 1994-02-01 1997-08-05 The Regents Of The University Of California Fluorescent labels and their use in separations
US5631734A (en) 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5571639A (en) 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5861293A (en) 1994-06-13 1999-01-19 Banyu Pharmaceutical Co., Ltd. Gene encoding glycosyltransferase and its uses
RU2111254C1 (en) 1994-07-11 1998-05-20 Институт молекулярной биологии им.В.А.Энгельгардта РАН Method of detection of differentially expressing template rnas and cloning the corresponding cdna fragments
US5710000A (en) 1994-09-16 1998-01-20 Affymetrix, Inc. Capturing sequences adjacent to Type-IIs restriction sites for genomic library mapping
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5922601A (en) 1995-01-19 1999-07-13 Biotransplant, Inc. High efficiency gene trap selection of regulated genetic loci
US5599695A (en) 1995-02-27 1997-02-04 Affymetrix, Inc. Printing molecular library arrays using deprotection agents solely in the vapor phase
US5753439A (en) 1995-05-19 1998-05-19 Trustees Of Boston University Nucleic acid detection methods
US5759776A (en) 1995-06-05 1998-06-02 California Pacific Medical Center Targets for breast cancer diagnosis and treatment
US5700644A (en) 1995-06-07 1997-12-23 Wisconsin Alumni Research Foundation Identification of differentially expressed genes
US5712126A (en) 1995-08-01 1998-01-27 Yale University Analysis of gene expression by display of 3-end restriction fragments of CDNA
US5733729A (en) 1995-09-14 1998-03-31 Affymetrix, Inc. Computer-aided probability base calling for arrays of nucleic acid probes on chips
US5776683A (en) 1996-07-11 1998-07-07 California Pacific Medical Center Methods for identifying genes amplified in cancer cells
US5968784A (en) 1997-01-15 1999-10-19 Chugai Pharmaceutical Co., Ltd. Method for analyzing quantitative expression of genes
US5994076A (en) 1997-05-21 1999-11-30 Clontech Laboratories, Inc. Methods of assaying differential expression

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997013877A1 (en) * 1995-10-12 1997-04-17 Lynx Therapeutics, Inc. Measurement of gene expression profiles in toxicity determination
WO1997027317A1 (en) * 1996-01-23 1997-07-31 Affymetrix, Inc. Nucleic acid analysis techniques
WO1998035041A1 (en) * 1997-02-06 1998-08-13 Incyte Pharmaceuticals, Inc. Human lea-motif developmental protein

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 29 October 1998 (1998-10-29), INCYTE PAHRM INC.: "human LEA motif developmental protein coding sequence", XP002141424 *
DATABASE EMBL embl heidelberg; 1 June 1999 (1999-06-01), LIN W.C.: "homo sapiens CGI-106 protein mRNA", XP002141423 *
YAMAGUCHI F. ET AL.,: "Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas", PROC. NATL. ACAD. SCI. USA, vol. 91, - January 1994 (1994-01-01), pages 484 - 488, XP002141422 *

Also Published As

Publication number Publication date
AU1724000A (en) 2000-05-29
WO2000028090A2 (en) 2000-05-18
US6440676B1 (en) 2002-08-27
US20030175734A1 (en) 2003-09-18
US6194158B1 (en) 2001-02-27

Similar Documents

Publication Publication Date Title
WO2000028090A3 (en) Diagnostic assay for cancer
WO2001036685A3 (en) Differential gene expression in cancer
MXPA03003151A (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer.
WO2002080754A3 (en) Methods for using annexin for detecting cell death in vivo and treating associated conditions
WO2003008583A3 (en) Novel compositions and methods for cancer
AU2001231199A1 (en) Compositions and methods for the early diagnosis of ovarian cancer
WO2003066802A3 (en) Gene expression analysis using nicking agents
WO2001072962A3 (en) Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
AU2001265296A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2004050707A3 (en) Tumor-specific recognition molecules
WO2003048301A3 (en) Anti-hla-dr antibodies and the methods of using thereof
WO2001075178A3 (en) Methods for identifying peptide aptamers capable of altering a cell phenotype
WO2002030465A3 (en) Compositions that inhibit proliferation of cancer cells
AU4224599A (en) Anti-prostate cancer vaccines, and methods of making, using and evaluating the same
WO1999020747A3 (en) HUMAN CHECKPOINT KINASE, hCDS1, COMPOSITIONS AND METHODS
WO2003045230A3 (en) Novel compositions and methods for cancer
WO2003057146A3 (en) Novel compositions and methods for cancer
WO1997029199A3 (en) Prostate specific antigen peptides and uses thereof
WO2001042792A3 (en) Diagnosis of cervical cancer using marker proteins
WO2001009384A3 (en) Serial analysis of genetic alterations
WO2003053224A3 (en) Novel compositions and methods for cancer
WO2005058251A3 (en) Hla-dr-specific antibodies, compositions and methods
AU3896899A (en) Compositions for the treatment of tumors, and uses thereof
WO2003035837A3 (en) Novel compositions and methods for cancer

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 17240

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase